The role of route of estrogen adminstration on the proliferation of SiHa cells in culture.
The specific objectives of this investigation were: (1) to evaluate the effect of estrogen on SiHa cervical cells delivered by TCPL delivery system versus conventional administration as a model for cervical cancer intervention and (2) to determine the estrogen dose effect on proliferation of these cells in culture. Estrogen was delivered for three time periods, 24, 48, and 72 hours both by conventional administration (direct administration) and drug delivery system using TCPL ceramic capsules. Three dosages of estrogen were selected (2, 10, and 100 pg/mL). Ceramic capsules were prepared using standard procedures (release profile 2, 10 or 100 pg/mL). Capsules were gas sterilized prior to being placed in the wells with cells. Data collected from this study indicated that, regardless of the route of administration, estrogen exposure did not induce major cellular injury at the 24 and 48 hour time period. Initially, there were various responses to estrogen among all groups compared to control. At 72 hours phase all experimental groups induced greater proliferation rate in the conventional delivery than in the groups exposed to sustained estrogen delivery. Low and medium doses conventionally added to the cells resulted in a decrease in cell number at 48 hours phase compared to the initial response at the 24 hours phase. With medium and high sustained delivery of estrogen rates, the data revealed that proliferation rate is directly proportional to duration of delivery compared to conventional means. The data suggest that the route of administration of estrogen is an instrumental tool in the prognosis of cervical cancer.
Brewer
Joyce
J
University of Mississippi Medical Center, Jackson, Mississippi 39216, USA.
Benghuzzi
Hamed
H
Tucci
Michelle
M
D000970:Antineoplastic Agents / Q000008:administration & dosage; D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D003692:Delayed-Action Preparations / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004967:Estrogens / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D009363:Neoplasm Proteins / Q000378:metabolism; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*
D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D004967:Estrogens; D009363:Neoplasm Proteins